Dear All: Just hitting my inbox today is this report from OHE. The paper reviews in detail the incentive proposals in the 2016 O’Neill Report on incentives from the UK AMR Review commissioned by UK government and the 2017 GUARD Report entitled “A Call for Concerted Action on Antibiotics Research and Development” commissioned by the German government. This well-written and detailed paper is a welcome
Dear All: First up, NIAID has released a BAA (Broad Agency Announcement) regarding up to $15.5m in funds for awards in two research areas. Here is a brief description … see below my signature for more details. To my eye, this looks like a very broad and inclusive call for proposals. Area 1: Development of Therapeutic Products for
This note was updated on 12 Jan 2018 to provide links to the videos from the bootcamp sessions. Dear All: GARDP + CARB-X have this week hosted Antibiotic Bootcamps #1, #2, and #3 at the ASM-ESCMID conference on antibiotic R&D. There were nearly 350 people registered for the full meeting with good attendance at each Bootcamp.
Dear All, The Duke-Margolis team hosted an excellent full-day workshop on 16 Jan 2020. Entitled “Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives” and chaired by Mark McClellan, the workshop’s outstanding cast of presenters and discussants provided a thorough discussion of both the need for new payment models and and the many ongoing activities focused
Dear All: Late last year, I had the opportunity to hear a presentation on antibiotic R&D in Japan by Norio Ohmagari. Based in Tokyo at the National Center for Global Health and Medicine Hospital (link), Norio is Director of its (i) AMR Clinical Reference Center, (ii) Disease Control and Prevention Center, and (iii) WHO Collaborating
Dear All, Warm up your chemistry set! NIAID has just released a pre-solicitation notice of their intent to request applications for a new NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). NIAID anticipates awarding a single CC4CARB contract funding 28,000 direct labor hours per year for up to 5 years. The core
Dear All, On Friday, 20 Dec 2020, legislation was signed to fund the US government through Sep 2020. Relevant to AMR: The bill provides a $50 million increase in funding to NIAID for antimicrobial resistance. NIAID will also have to report to Congress on the success rate for these particular grants. The bill provides funding for
Dear All, Two important new research calls are now out. First, FDA is offering research funding of up to $1m to support creation of rabbit models of ventilator-associated bacterial pneumonia (VAP or VABP, depending on your preferred abbreviation) due to carbapenem-resistant strains of A. baumannii and P. aeruginosa. The call for proposals is via FDA Broad Agency Announcement (FDABAA-20-00123N, link), an ongoing
Dear All, As part of a NIAID Omnibus Broad Agency Announcement (BAA) posted on 31 Dec 2019, NIAID’s Division of Microbiology and Infectious Diseases (DMID, link) has three research areas (RAs) soliciting contract proposals for preclinical and clinical development of vaccines, therapeutic, and diagnostics for microbial pathogens. The entire BAA can be found here. The three RAs
Dear All, I realized after sending the note about Melinta’s bankruptcy that I’d failed to be clear on what comes next for the company. (If you missed it, you can go here for a copy of that prior note.) In brief, a 27 Dec 2019 press release (link) states that the bankruptcy filing exchanges $140 million of secured claims